In This Section
Search/Filter
Category
AACR Career Development AwardsAACR Research GrantsGrantee ImpactGrantee NewsGrantee StoryGrants News
Back to Grantees
Loading...
SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.

Category: Grantee Impact
Learn More
Bispecific Anti-PD-1/PD-L1 Antibody’s Dual Impact in Ovarian Cancer

Bispecific Anti-PD-1/PD-L1 Antibody’s Dual Impact in Ovarian Cancer

Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...

Category: Grantee Impact
Learn More